Novartis subsidiary Hexal has finally launched its OTC desloratadine product after winning an important case against Germany’s Ministry of Health for the drug’s release from prescription-only status.
Despite having received a positive recommendation from Germany’s Expert Committee for Prescription, the Ministry of Health, BMG, blocked the prescription-to-pharmacy-only switch of desloratadine in 2013
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?